Front Page News
Updated SMA Drug Pipeline Released as First Commercial Patient Receives Spinraza
With the news today that the first-ever patient has received the first commercial Spinraza dose, we are releasing an updated version of our SMA drug […]
SMA Patient-Focused Drug Development Meeting with FDA Set for April 18, 2017
Tuesday, April 18, 2017, has been announced as the date for the SMA Patient-Focused Drug Development Meeting with the FDA. At the Patient Focused Drug […]
Cure SMA Assists Hundreds of Families in 2016
Each year, Cure SMA provides thousands of families with vital support and resources to help them live active, engaged and hopeful lives. Our programs provide […]
Cure SMA Funding Results in 16 New Research Publications
An important goal of our research funding strategy is to share scientific findings with the broader scientific community. To help accomplish this goal, scientists who […]
2016 Research Year-in-Review: An Historic Year for Our Community
This has been an historic year for the SMA community. On December 23, the FDA announced its approval of Spinraza, the first-ever approved treatment for […]
Biogen Resources for the SMA Community
Biogen has provided the following update on resources they have made available for the SMA community: Biogen recently announced that the U.S. Food and Drug […]
Join Us for an Upcoming Webcast about SPINRAZA TM (nusinersen)
Please join Cure SMA, MDA and representatives from Biogen to learn more about SPINRAZA™ (nusinersen). As you know, SPINRAZA recently received FDA approval in the […]
Biogen Provides Community Statement and Q&A on the Approval of Spinraza for SMA
Biogen provided the following statement on the approval of Spinraza for SMA: Dear Members of the SMA Community, Today, the SMA community achieved a goal […]
Ionis Pharmaceuticals Issues Community Statement on the Approval of Spinraza
Ionis Pharmaceuticals has issued the following community statement on the approval of Spinraza for SMA: Dear Members of the SMA Community, Today is a historic […]
FDA Approves Spinraza for SMA
On December 23, the FDA announced that it has approved SpinrazaTM (nusinersen) to treat spinal muscular atrophy, making it the first-ever FDA-approved therapy for SMA. […]